The assessment of acute phase proteins as prognostic factors in patients surgically treated for non-small cell lung cancer;Ocena wybranych biatek ostrej fazy jako czynników rokowniczych u chorych leczonych chirurgicznie z powodu niedrobnokomórkowego raka płuca

Pneumonologia i Alergologia Polska

Volumn 76, Issue 5, 2008, Pages 321-326

  Kasprzyk, Mariusz ^a   Dyszkiewicz, Wojciech ^a   Zwaruń, Damian ^a   Leśniewska, Kinga ^a   Wiktorowicz, Krzysztof ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Acute phase proteins; Lung cancer; Prognostic factors; Surgical treatment

Indexed keywords

ACUTE PHASE PROTEIN; ALPHA 2 MACROGLOBULIN; C REACTIVE PROTEIN; CERULOPLASMIN; HAPTOGLOBIN; OROSOMUCOID; TUMOR MARKER;

ADENOCARCINOMA; AGED; ARTICLE; BLOOD; CANCER STAGING; FEMALE; HUMAN; IMMUNOELECTROPHORESIS; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; PATHOLOGY; POLAND; SQUAMOUS CELL CARCINOMA;

ACUTE-PHASE PROTEINS; ADENOCARCINOMA; AGED; ALPHA-MACROGLOBULINS; C-REACTIVE PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CERULOPLASMIN; FEMALE; HAPTOGLOBINS; HUMANS; IMMUNOELECTROPHORESIS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OROSOMUCOID; POLAND; TUMOR MARKERS, BIOLOGICAL;

EID: 57049153508     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Baumann H., Gauldie J. The acute phase response. Immunol. Today 1994; 15: 74-80.
2. D'Armiento J., Dalal S.S., Chada K. Tissue, temporal and inducible expression pattern of haptoglobin in mice. Gene 1997; 195: 19-27.
3. Kushner I., Mackiewicz A. Acute phase proteins as disease markers. Dis. Markers 1987; 5: 1-11.
4. Kushner I. The phenomenon of the acute phase response. Ann. NY Acad. Sci. 1982; 389: 39-48.
5. Grenier A., Dohoux M., Boutten A. i wsp. Oncostatin M production end regulation by human polymorphonuclear neutrophils. Blood 1999; 93: 1413-1421.
6. Streelz K.L., Wustefeld T., Klein C. i wsp. Mediators of Inflammation and acute phase response in the liver. Cell. Mol. Biol. 2001; 47: 661-73.
7. Atwell D.M., Grichnik K.P., Newman M.V, i wsp. Balance of proinflammatory and antiinflammatory cytokines at thoracic cancer operation. Ann. Thorac. Surg. 1998; 86: 1145-1150.
8. Smith U.R., Kunkel S.L., Burdick M.D. Production of IL-10 by human bronchogenic carcinoma. Am, J. Path. 1994; 145: 18-25.
9. Bruno R., Olivaros R., Berille J. i wsp. Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docotaxel. Clin. Cancer Res. 2003; 9: 1077-1082.
10. De Vita F., Orditura M., Galizia G. i wsp. Serum Interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest 2000; 117: 365-373.
11. Kaminźska J., Kowalska M., Kotowicz B. i wsp. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer and correlations with clinicopathological features and prognosis. Oncology 2006; 70: 115-125.
12. Yildirim A., Meral M., Kaynar H. i wsp, Relationship between serum levels of some acute-phase proteins and stage of disease and performance status in patients with lung cancer. Med. Sci, Monit. 2007; 13: 195-200.
13. Khan N., Cromer C.J., Campa M. i wsp. Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of non-small cell lung carcinoma. Cancer 2004; 101: 379-384,
14. McKeown DJ., Brown D.J., Kelly A. i wsp. The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small cell lung cancer. Br. J. Cancer 2004; 91: 1993-1995.
15. Siemes C., Visser L.E., Coebergh J.W. i wsp. C-reactive protein levels, variation in the C-reactive protein gene and cancer risk: the Rotterdam Study. J. Clin. Oncol. 2006; 24: 5216-5222.
16. Songur N., Kuru B., Kalkan F. i wsp. Serum lnterleukin-6 levels correlate with malnutrition and survival in patients with anvanced non-small cell lung cancer. Tumori 2004; 90: 196-200.
17. Tas F., Duranyildiz D., Argon A. i wsp. Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer. Med. Oncol. 2005; 22: 353-358.
18. Christou N.V., Meakins J.L. Phagocytic and baktericidal functions of polymorphonuclear neutrophils from anergic surgical patients. Can. J. Surg. 1982; 25: 444-448.
19. Craig S.R., Leaver H.A., Yap P.L. i wsp. Acute phase responses following minimal access and conventional thoracic surgery. Eur. J. Cardio. Thorac. Surg. 2001; 20: 455-463.
20. Pollock R.E., Lotzova E., Stanford S.D. Surgical stress impairs natural killer cell programing of tumour for lysis in patients with sarcomas and other solid tumours. Cancer 1992; 70: 2192-2202.
21. Arias-Diaz J., Vara E., Torres-Melero J. Nitrite/nitrate and cytokine levels in bronchoalveolar lavage fluid of lung cancer patients. Cancer 1994; 74: 1546-1551.
22. Martinet N., Charles T., Vaillant P. Characterisation of a tumor necrosis factor-alpha inhibitor activity in cancer patients. Am. J. Respir. Cell. Mol. Biol. 1992; 6: 510-515.
23. Partanen R., Koskinen H., Hemminki K. Tumor necrosis factor-alpha (TNF-alpha) in patients who have asbestosis and develop cancer. Occup. Environ. Med. 1995; 52: 316-319.
24. Liu D.H., Wang X.M., Zhang L.J. i wsp. Serum amyloid A protein: a potential biomarker correlated with clinical stage of lung cancer. Biomed. Environ. Sci. 2007; 20: 33-40.
25. Bhartl A., Ma P.C., Maulik G. I wsp. Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer, Anticancer Res. 2004; 24: 1031-1038.